HIV vaccine - Amgen/NIAID

Drug Profile

HIV vaccine - Amgen/NIAID

Alternative Names: AIDS vaccine - Amgen/NIAID; Prophylactic HIV vaccine - Amgen/NIAID

Latest Information Update: 16 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioVex; National Institute of Allergy and Infectious Diseases
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 27 Apr 2006 No development reported - Preclinical for HIV infections prevention in United Kingdom (unspecified route)
  • 27 Apr 2006 No development reported - Preclinical for HIV infections prevention in USA (unspecified route)
  • 16 May 2003 Preclinical trials in HIV infections prevention in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top